Gastric cancer cell line derived from murine gastric adenocarcinoma lacking p53 and E-cadherin and use thereof
US9683987B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 29, 2016 |
| Grant date | Jun 20, 2017 |
| Priority date | — |
| Expiry date | Jan 29, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/57446
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Provided is a gastric cancer cell line derived from a mouse deficient in E-cadherin and p53, and a use thereof. The E-cadherin- and p53-deficient, murine-derived gastric cancer cell line of the present invention was confirmed to have histopathological characteristics similar to those of human gastric cancer, have an epithelial mesenchymal transition (EMT) phenotype and an activated β-catenin pathway, and promote cancer growth in vivo due to potential of carcinogenesis, and thus the gastric cancer cell line of the present invention can be effectively used for the evaluation of the activity of new anticancer drugs and the development of metastasis inhibitors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.